Evolving therapeutic paradigms for HIV and HCV

Akhteruzzaman Molla; William Kohlbrenner

doi:10.1016/j.copbio.2003.10.012

Evolving therapeutic paradigms for HIV and HCV

Curr Opin Biotechnol. 2003 Dec;14(6):634-40. doi: 10.1016/j.copbio.2003.10.012.

Authors

Akhteruzzaman Molla¹, William Kohlbrenner

Affiliation

¹ Antiviral Research, Global Pharmaceuticals Research & Development, Abbott Laboratories, Department R47D, Building AP52N, 200 Abbott Park Road, Abbott Park, IL 60064-6217, USA. [email protected]

PMID: 14662394
DOI: 10.1016/j.copbio.2003.10.012

Abstract

The continued development of enabling molecular technologies that can be employed to better understand viral replication and the action of currently available therapeutic agents promises to lead to the development of the next generation of drugs with improved therapeutic utility against human immunodeficiency virus (HIV) and hepatitis C virus (HCV). New therapeutic approaches have been developed for treating HIV and HCV infections, but key technical and therapeutic challenges must be addressed to further advance treatment options in each of these areas.

Publication types

Review

MeSH terms

Antiretroviral Therapy, Highly Active
Antiviral Agents / pharmacology
Antiviral Agents / therapeutic use*
Drug Design
Drug Therapy, Combination
HIV Fusion Inhibitors / pharmacology
HIV Fusion Inhibitors / therapeutic use
HIV Infections / drug therapy
Hepatitis C / drug therapy*
Humans
Integrase Inhibitors / pharmacology
Integrase Inhibitors / therapeutic use
Protease Inhibitors / pharmacology
Protease Inhibitors / therapeutic use

Substances

Antiviral Agents
HIV Fusion Inhibitors
Integrase Inhibitors
Protease Inhibitors